prikaz prve stranice dokumenta Uloga proteina ADAR1 u replikaciji humanoga herpes virusa 8 (HHV-8)
  Download
PDF 2.82 MB
undergraduate thesis
Uloga proteina ADAR1 u replikaciji humanoga herpes virusa 8 (HHV-8)
2023. urn:nbn:hr:193:225655
Fadiga, Hana
University of Rijeka
Faculty of Biotechnology and Drug Development

Cite this document

Fadiga, H. (2023). Uloga proteina ADAR1 u replikaciji humanoga herpes virusa 8 (HHV-8) (Undergraduate thesis). Rijeka: University of Rijeka. Retrieved from https://urn.nsk.hr/urn:nbn:hr:193:225655

Fadiga, Hana. "Uloga proteina ADAR1 u replikaciji humanoga herpes virusa 8 (HHV-8)." Undergraduate thesis, University of Rijeka, 2023. https://urn.nsk.hr/urn:nbn:hr:193:225655

Fadiga, Hana. "Uloga proteina ADAR1 u replikaciji humanoga herpes virusa 8 (HHV-8)." Undergraduate thesis, University of Rijeka, 2023. https://urn.nsk.hr/urn:nbn:hr:193:225655

Fadiga, H. (2023). 'Uloga proteina ADAR1 u replikaciji humanoga herpes virusa 8 (HHV-8)', Undergraduate thesis, University of Rijeka, accessed 29 December 2024, https://urn.nsk.hr/urn:nbn:hr:193:225655

Fadiga H. Uloga proteina ADAR1 u replikaciji humanoga herpes virusa 8 (HHV-8) [Undergraduate thesis]. Rijeka: University of Rijeka; 2023 [cited 2024 December 29] Available at: https://urn.nsk.hr/urn:nbn:hr:193:225655

H. Fadiga, "Uloga proteina ADAR1 u replikaciji humanoga herpes virusa 8 (HHV-8)", Undergraduate thesis, University of Rijeka, Rijeka, 2023. Available at: https://urn.nsk.hr/urn:nbn:hr:193:225655

Please login to the repository to save this object to your list.
Metadata
TitleUloga proteina ADAR1 u replikaciji humanoga herpes virusa 8 (HHV-8)
AuthorHana Fadiga
MentorIgor Jurak (mentor)
Committee memberMladen Merćep (predsjednik povjerenstva)
Committee memberNicholas James Bradshaw (član povjerenstva)
GranterUniversity of Rijeka
(Faculty of Biotechnology and Drug Development)
Rijeka
Defense date and country2023-07-11, Croatia
Scientific / art field,
discipline and subdiscipline		BIOTECHNICAL SCIENCES
Biotechnology
Abstract
Jedna od najčešćih posttranskripcijskih modifikacija na dvolančanoj RNA (dsRNA) kod ljudi jest proces prelaska adenozina u inozin (A-I uređivanje). Deaminaciju kataliziraju adenozin deaminaze koje djeluju na RNA (ADAR). ADAR geni kodiraju četiri izoforme ADAR proteina: ADAR1- p110, ADAR1-p150, ADAR2 i ADAR3. Istraživanja su pokazala da je ekspresija ADAR1 na uređenim mjestima najviša zbog čega se smatra da ima ključnu ulogu u promjenama u ekspresiji RNA kao i njezinoj funkciji. Uređivanje A-I putem ADAR-a ima velik učinak na očuvanje stanične homeostaze, dok se abnormalnosti u uređivanju povezuju s patogenezom brojnih bolesti, uključujući autoimune bolesti i tumore. ADAR svoju ključnu ulogu pokazuje u regulaciji imunološkoga odgovora domaćina i kontroliranju replikacije virusa. Ovisno o specifičnome virusu te kombinaciji stanica domaćina, uređivanje može imati provirusne ili antivirusne učinke. Kaposijev sarkom povezan s herpesvirusom (KSHV) primjer je virusa kod kojega ADAR1 ima provirusni učinak. KSHV je dvolančani DNA virus povezan s Kaposijevim sarkomom (KS), primarnim efuzijskim limfomom (PEL) i multicentričnim Castlemanovom bolešću (MCD) koji tijekom svojega životnog ciklusa prolazi kroz dvije faze: latentnu i litičku. Tijekom latentne faze ekspresija gena je uvelike ograničena. Uređivanje jednoga od transkripata ekspresioniranoga u latentnoj fazi, K12 RNA, s pomoću ADAR1 eliminira njegov onkogeni potencijal. Nakon reaktivacije KSHV-a slijedi litička faza kada se ekspresija gena povećava i aktivira se urođeni imunološki odgovori domaćina koji sprječava replikaciju virusa. S obzirom na to da je reaktivacija povezana s aktivnošću interferona (IFN) te ADAR1 utječe na nju, dovodi se u pitanje ako ADAR1 kontrolira aktivaciju signalnoga puta receptora sličnih RIG-u (RLR). Potvrđeno je da povećane razine ADAR1 proteina smanjuje urođeni imunološki odgovori na RNA što utječe na proliferaciju virusa.
Abstract (english)
One of the most common post-transcriptional modifications of double-stranded RNA (dsRNA) in humans is the conversion of adenosine to inosine (A-I editing). Deamination is catalyzed by RNA-acting adenosine deaminase (ADAR). ADAR genes encode four isoforms of ADAR proteins. ADAR1-p110, ADAR1-p150, ADAR2, and ADAR3. According to studies, ADAR1 expression is more abundant in regulatory locations, indicating that ADAR1 is crucial for modifying RNA expression and function. The cellular homeostasis-maintaining role of A-I editing by ADARs is significant, while abnormal editing is thought to play a role in the development of a wide range of illnesses, including cancers and autoimmune diseases. ADARs are crucial for controlling viral replication and modulating host immunological responses. Editing can have proviral or antiviral effects, depending on the particular virus and host cell combination. A virus in which ADAR1 has a proviral effect is Kaposi's sarcoma-associated herpesvirus (KSHV). KSHV is a double-stranded DNA virus that goes through two stages of its life cycle: latent and lytic phase. It is linked to Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD). During latency, gene expression is severely restricted. Editing of K12 RNA, one of the latently expressed transcripts, by ADAR1, eliminates its oncogenic potential. KSHV reactivation is followed by a lytic phase, during which the host's innate immune response is triggered and gene expression rises, allowing the virus to proliferate. Since reactivation of the RIG-like receptor (RLR) signaling pathway is linked to IFN activity, which ADAR1 affects, it has been questioned if ADAR1 regulates it. It has been shown that elevated ADAR1 protein levels diminish innate immune responses to RNAs that affect viral replication.
Keywords
Languagecroatian
URN:NBNurn:nbn:hr:193:225655
Study programmeTitle: Biotechnology and drug research
Study programme type: university
Study level: undergraduate
Academic / professional title: sveučilišni/a prvostupnik/prvostupnica biotehnologije i istraživanja lijekova (sveučilišni/a prvostupnik/prvostupnica biotehnologije i istraživanja lijekova)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2023-07-10 15:10:56